Asset profile

PUR1900 · Pulmatrix, Inc. (PULM)

Indication
allergic bronchopulmonary aspergillosis (ABPA) and other fungal infections
CompanyPULMPulmatrix, Inc.

Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, …

On the calendar

Nothing scheduled in this window.

Timeline

Newest first.

Registered trials

Registry IDPhaseStatusPrimary completionEnrollmentSites
NCT03960606Phase 2TerminatedJul 14, 202079 of 20 sites in the United States
PUR1900 · Pulmatrix, Inc. (PULM) — FDA Timeline & Readiness Checklist | SimianX AI